Novo Holdings has completed its $16.5 billion acquisition of Catalent, the contract drug manufacturer said on Wednesday, days ...

Novo Holdings has completed the previously announced acquisition of Catalent in a $16.5bn all-cash transaction. The European ...

StockNews.com began coverage on shares of Catalent (NYSE:CTLT – Free Report) in a research report sent to investors on Friday ...

Shares of Catalent, Inc. (NYSE:CTLT – Get Free Report) have been given an average rating of “Hold” by the seven analysts that are presently covering the company, Marketbeat.com reports. Seven analysts ...

The latest announcement is out from Catalent ( (CTLT) ).

BRUSSELS (Reuters) -Novo Holdings on Friday gained unconditional EU antitrust approval for its $16.5 bln acquisition of U.S. contract drug maker Catalent after EU regulators said they did not see any ...

Catalent, Inc. (“Catalent,” NYSE: CTLT), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Holdings A/S (“Novo Holdings”), a global life ...

Catalent (NYSE:CTLT) rose 1.6% after a report that the contract drug manufacturer's $16.5 billion sale to Novo Holdings could close as soon as Monday. The US Federal Trade Commission doesn't ...

Indications are that Novo will be investing in both the plant and the community,” an Indiana University professor said.

SOMERSET, N.J. & COPENHAGEN, Denmark, December 06, 2024--(BUSINESS WIRE)--Catalent, Inc. ("Catalent," NYSE: CTLT), a leader in enabling the development and supply of better treatments for patients ...